Loading [Contrib]/a11y/accessibility-menu.js

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Skip to main content
null
Clinical Hematology International
  • Menu
  • Articles
    • Case Report
    • Case study
    • Correspondence
    • Editorial
    • General
    • Original Research Articles
    • Perspective Article
    • Research Articles
    • Retrospective study
    • Review Articles
    • Survey
    • Systematic Reviews
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Blog
  • Conference-Event-Webinar
  • Reviewer Information
  • Open Access Policies
  • search
  • X (formerly Twitter) (opens in a new tab)
  • LinkedIn (opens in a new tab)
  • RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

https://chi.scholasticahq.com/feed
ISSN 2590-0048
General
Vol. 4, Issue 1-2, 2022May 23, 2022 CDT

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia

Obada Ababneh, Hassan Abushukair, Aref Qarqash, Sebawe Syaj, Samer Al Hadidi,
Waldenstrom’s MacroglobulinemiaBruton tyrosine kinase inhibitorsIbrutinibZanubrutinib
Copyright Logoccby-4.0 • https://doi.org/10.1007/s44228-022-00007-5
Clinical Hematology International
Ababneh, Obada, Hassan Abushukair, Aref Qarqash, Sebawe Syaj, and Samer Al Hadidi. 2022. “The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia.” Clinical Hematology International 4 (1–2): 21–29. https:/​/​doi.org/​10.1007/​s44228-022-00007-5.

View more stats

Powered by Scholastica, the modern academic journal management system